THE RISK OF ANTIDEPRESSANT-INDUCED HYPONATREMIA: A META- ANALYSIS OF ANTIDEPRESSANT CLASSES AND COMPOUNDS

Abstract Background Hyponatremia (hypoNa) is a potentially serious adverse event of treatment with antidepressants. Previous research suggests that risk of drug-induced hyponatremia differs between antidepressants.1 This meta-analysis sought to determine the risk of antidepressant-induced hypoNa, stratified by different compounds and classes. Methods PubMed and Web of Science were searched for studies reporting on incidence or risk of hypoNa in adults using antidepressants (PROSPERO, CRD42021269801). We modelled random-effects meta- analyses to compute overall incidence and risk of any and clinically relevant hypoNa for each compound and class, and ran head-to-head comparisons based on hypoNa incidences. We conducted subgroup analyses for geriatric populations, study context and sodium cut-off value. Results We included 39 studies (n = 8,175,125). Exposure to antidepressants was associated with significantly increased odds of hypoNa (k = 7 studies, OR = 3.160 (1.911-5.225)). The highest event rates were found for SNRIs (5.31%), SSRIs (5.18%), and TCAs (2.18%); the lowest for mirtazapine (1.02%) and trazodone (0.89%). The highest odds ratios were found for MAOIs (3.789 (1.602 – 8.966)), SNRIs (2.969 (1.717 – 5.136)), and SSRIs (2.842 (1.564 – 5.164)); the lowest for mirtazapine (2.818 (1.886 – 4.211)) and TCAs (1.803 (1.252 – 2.598)). Compared to SSRIs, SNRIs were significantly more likely (k = 9, OR = 1.268 (1.129 – 1.425), p <0.001) and mirtazapine significantly less likely (k = 9, OR = 0.607 (0.385 – 0.957), p = 0.032) associated with hypoNa. Conclusion Our meta-analysis demonstrated that, while no antidepressant can be considered completely risk-free, for hypoNa-prone patients mirtazapine should be considered the treatment of choice and SNRIs should be prescribed more cautiously than SSRIs and TCAs. References 1.De Picker L, Van den Eede F, Dumont G, Moorke G, Sabbe BGC. Antidepressants and the Risk of Hyponatremia: A Class-by-Class Review of Literature. Psychosomatics. 2014;55(6):536-47.

Authors

Institutions

Publication Details

Journal
The International Journal of Neuropsychopharmacology
Published
2025-02-01
DOI
https://doi.org/10.1093/ijnp/pyae059.034
Citations
2
Primary Topic
Electrolyte and hormonal disorders
Type
article
Field-Weighted Citation Impact
3.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

THE RISK OF ANTIDEPRESSANT-INDUCED HYPONATREMIA: A META- ANALYSIS OF ANTIDEPRESSANT CLASSES AND COMPOUNDS

Filip Van Den Eede, Livia De Picker, Tim Gheysens
2 citations
The International Journal of Neuropsychopharmacology
Electrolyte and hormonal disorders
3.04
article

THE RISK OF ANTIDEPRESSANT-INDUCED HYPONATREMIA: A META- ANALYSIS OF ANTIDEPRESSANT CLASSES AND COMPOUNDS

Filip Van Den Eede, Livia De Picker, Tim Gheysens
article en
2 citations

Abstract

Abstract Background Hyponatremia (hypoNa) is a potentially serious adverse event of treatment with antidepressants. Previous research suggests that risk of drug-induced hyponatremia differs between antidepressants.1 This meta-analysis sought to determine the risk of antidepressant-induced hypoNa, stratified by different compounds and classes. Methods PubMed and Web of Science were searched for studies reporting on incidence or risk of hypoNa in adults using antidepressants (PROSPERO, CRD42021269801). We modelled random-effects meta- analyses to compute overall incidence and risk of any and clinically relevant hypoNa for each compound and class, and ran head-to-head comparisons based on hypoNa incidences. We conducted subgroup analyses for geriatric populations, study context and sodium cut-off value. Results We included 39 studies (n = 8,175,125). Exposure to antidepressants was associated with significantly increased odds of hypoNa (k = 7 studies, OR = 3.160 (1.911-5.225)). The highest event rates were found for SNRIs (5.31%), SSRIs (5.18%), and TCAs (2.18%); the lowest for mirtazapine (1.02%) and trazodone (0.89%). The highest odds ratios were found for MAOIs (3.789 (1.602 – 8.966)), SNRIs (2.969 (1.717 – 5.136)), and SSRIs (2.842 (1.564 – 5.164)); the lowest for mirtazapine (2.818 (1.886 – 4.211)) and TCAs (1.803 (1.252 – 2.598)). Compared to SSRIs, SNRIs were significantly more likely (k = 9, OR = 1.268 (1.129 – 1.425), p <0.001) and mirtazapine significantly less likely (k = 9, OR = 0.607 (0.385 – 0.957), p = 0.032) associated with hypoNa. Conclusion Our meta-analysis demonstrated that, while no antidepressant can be considered completely risk-free, for hypoNa-prone patients mirtazapine should be considered the treatment of choice and SNRIs should be prescribed more cautiously than SSRIs and TCAs. References 1.De Picker L, Van den Eede F, Dumont G, Moorke G, Sabbe BGC. Antidepressants and the Risk of Hyponatremia: A Class-by-Class Review of Literature. Psychosomatics. 2014;55(6):536-47.

The International Journal of NeuropsychopharmacologyVol. 28(Supplement_1)
University of Antwerp (BE), Antwerp University Hospital (BE), University Psychiatric Hospital (SI)
Openalex Percentile: Top 11%
Electrolyte and hormonal disorders
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.